SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Cathcart who wrote (181)9/15/1997 6:42:00 PM
From: seminole   of 1826
 
David

The interest seems to be increasing. I have an opinion
about what is going on with the second Phase I trail
based on your post after communicating with people in the
company.

I believe you have a good but conservative group running
the company. Their experience is with small markets and
products. They come across a patent and lab results were
there are several drug analogs and scatterred results on a
wide range of cell types.

How I would expect them to act, is to define and limit
the scope of their study to one drug and one or two cell lines.
This would save time and money. So they started a Phase I study
intending to study one type of cancer at a time in phase II.
But after giving the drug to the NCI they get a new partner for
Phase II studies and the ablity to study several different types
of cancer. So Phase I studies are being expanded based
the new resources available in Phase II.

richard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News